Business
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at
About this update from Abcellera Biologics Inc.
[{"type":"text","content":" VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19.\n\nAbCellera will present the complete characterization of its panel of differentiated CD3-binding antibodies and demonstrate how it enables customized design of T-cell engagers for cancer targets. Additionally, AbCellera will present data on the discovery and characterization of antibodies against MAGE-A4, a validated peptide-MHC (pMHC) target for cancer treatment. Together, these two presentations illustrate how AbCellera’s CD3 panel integrates with its antibody discovery and development engine to streamline T-cell engager development.\n\nDetails on AbCellera’s poster presentations at AACR are as follows:\n\nTitle: Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies\nAbstract Number: 1886\nDate and Time: Monday, April 17 from 9:00 a.m. to 12:30 p.m. ET\n\nTitle: Breaking barriers to access intracellular targets with T-cell engagers: Discovery of diverse, developable, and ultra-specific antibodies against a MAGE-A4 pMHC\nAbstract Number: 1891\nDate and Time: Monday, April 17 from 9:00 a.m. to 12:30 p.m. ET\n\nAbout AbCellera Biologics Inc.\nAbCellera searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com\n\nAbCellera Forward-Looking Statements\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including stateme...